Podiatrists in Port Angeles, WA Accepting Medicare
6 Podiatrists found. Showing 1 - 6
 Samuel Liebson, D.P.M. Podiatrist - Foot Surgery Medicare: Accepting Medicare Assignments Practice Location: 1597 Deer Park Rd, Port Angeles, WA 98362 Phone: 360-452-6428 Fax: 360-457-9012 |
 Olga Drogomiretskiy Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-417-1599 |
Mckay Jared Davis, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-457-1599 |
Dr. Bradley M Pederson, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 630 E 8th St, Port Angeles, WA 98362 Phone: 360-457-1772 Fax: 360-457-9320 |
Adam Joseph Killpack, DO Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-457-1599 |
Dr. Dekker Nolan Mckeever, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 Fax: 360-457-1599 |
News Archive
ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.
Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab
New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.
Minimally invasive scopes to detect cancer
Just as cameras and televisions have been reinvented in the last decade with improved optics, sharpness and brightness, so have the tiny imaging scopes that physicians use to peer into the body's nooks and crannies - its organs and digestive system.
CDP-choline may block skull and brain damage that result from alcohol consumption early in pregnancy
The dietary supplement CDP-choline, sold as a brain-boosting agent and under study for stroke and traumatic brain injury, may block skull and brain damage that can result from alcohol consumption early in pregnancy, Medical College of Georgia researchers report.
› Verified 7 days ago
Physical Therapists
Chiropractors
Optometrists
Occupational Therapists
Speech-Language Pathologists
Podiatrists